BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 2007;12:321-30. [PMID: 17635745 DOI: 10.1111/j.1440-1797.2007.00810.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 73] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Fusaro M, D’angelo A, Naso A, Frigo AC, Miozzo D, Gallieni M, Calò LA. Treatment with Calcimimetic (Cinacalcet) Alters Epoetin Dosage Requirements in Dialysis Patients: Preliminary Report. Renal Failure 2011;33:732-5. [DOI: 10.3109/0886022x.2011.589937] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM; HERO Study Collaborative Group. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. Am J Kidney Dis 2015;65:49-57. [PMID: 25115616 DOI: 10.1053/j.ajkd.2014.06.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
3 Barraclough KA, Brown F, Hawley CM, Leary D, Noble E, Campbell SB, Isbel NM, Mudge DW, van Eps CL, Johnson DW. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrol Dial Transplant 2012;27:4146-53. [PMID: 22962411 DOI: 10.1093/ndt/gfs372] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
4 Akizawa T, Ueno M, Shiga T, Reusch M. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies. Ther Apher Dial 2020;24:628-41. [PMID: 31891449 DOI: 10.1111/1744-9987.13468] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
5 Suttorp MM, Hoekstra T, Rotmans JI, Ott I, Mittelman M, Krediet RT, Dekker FW. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol 2013;14:200. [PMID: 24066978 DOI: 10.1186/1471-2369-14-200] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
6 Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis. 2009;16:143-151. [PMID: 19233073 DOI: 10.1053/j.ackd.2008.12.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
7 Pramod S, Goldfarb DS. Challenging patient phenotypes in the management of anaemia of chronic kidney disease. Int J Clin Pract 2021;:e14681. [PMID: 34331826 DOI: 10.1111/ijcp.14681] [Reference Citation Analysis]
8 Clark B, Woolford SM, Eastwood A, Sharpe K, Barnes PG, Gore CJ. Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin: Temporal responses to high- and micro-doses of rHuEPO. Drug Test Analysis 2017;9:1561-71. [DOI: 10.1002/dta.2176] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
9 Kutuby F, Wang S, Desai C, Lerma EV. Anemia of chronic kidney disease. Dis Mon 2015;61:421-4. [PMID: 26364946 DOI: 10.1016/j.disamonth.2015.08.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
10 Barratt J, Sulowicz W, Schömig M, Esposito C, Reusch M, Young J, Csiky B. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Adv Ther 2021;38:5345-60. [PMID: 34523074 DOI: 10.1007/s12325-021-01903-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lo WK. Latest Strategy in Renal Anemia Management in Peritoneal Dialysis Patients. Perit Dial Int 2008;28:76-80. [DOI: 10.1177/089686080802803s16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. Am J Kidney Dis. 2016;67:912-924. [PMID: 26846333 DOI: 10.1053/j.ajkd.2015.12.020] [Cited by in Crossref: 133] [Cited by in F6Publishing: 121] [Article Influence: 22.2] [Reference Citation Analysis]
13 Winnicki W, Prehslauer A, Kletzmayr J, Herkner H, Sunder-Plassmann G, Brunner M, Hörl WH, Sengoelge G. Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. Eur J Clin Invest 2012;42:1087-93. [PMID: 22845880 DOI: 10.1111/j.1365-2362.2012.02699.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Won HS, Choi SJ, Yun YS, Shin OR, Ko YH, Kim YS, Yoon SA, Kim YO. Resistance to erythropoiesis-stimulating agents is associated with arterial microcalcification in early hemodialysis patients. Biomed Res Int 2014;2014:731296. [PMID: 24772434 DOI: 10.1155/2014/731296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Yan X, Ait-Oudhia S, Krzyzanski W. Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness. Pharm Res 2013;30:1026-36. [PMID: 23187865 DOI: 10.1007/s11095-012-0938-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Yousaf F, Spinowitz B. Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin? Curr Hypertens Rep 2016;18. [DOI: 10.1007/s11906-016-0629-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ghobrial EE, Salama KM, Shiba MF, El Shafae NH. The effect of anemia management on chronic renal failure progression. Egyptian Pediatric Association Gazette 2013;61:37-41. [DOI: 10.1016/j.epag.2013.04.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K, Wolf M, Hirakata H. Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep 2019;9:8877. [PMID: 31222044 DOI: 10.1038/s41598-019-45335-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
19 Csiky B, Schömig M, Esposito C, Barratt J, Reusch M, Valluri U, Sulowicz W. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES). Adv Ther 2021;38:5361-80. [PMID: 34537926 DOI: 10.1007/s12325-021-01904-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Nishio A, Chhatkuli BP, Ma JZ, Kalantari K. Higher Doses of Erythropoietin-Stimulating Agents and Hyporesponsiveness to Their Effects Are Associated with Increased Mortality among Prevalent Hemodialysis Patients. Blood Purif 2013;36:29-36. [DOI: 10.1159/000350583] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
21 Charytan C. Bundled-Rate Legislation for Medicare Reimbursement for Dialysis Services: Implications for Anemia Management with ESAs. CJASN 2010;5:2355-62. [DOI: 10.2215/cjn.04820610] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
22 Means RT. Anemia of Renal Failure/Chronic Kidney Disease. In: Means RT, editor. Anemia in the Young and Old. Cham: Springer International Publishing; 2019. pp. 147-56. [DOI: 10.1007/978-3-319-96487-4_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
23 Garrido P, Ribeiro S, Fernandes J, Vala H, Rocha-Pereira P, Bronze-da-Rocha E, Belo L, Costa E, Santos-Silva A, Reis F. Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. Int J Mol Sci 2015;17:E28. [PMID: 26712750 DOI: 10.3390/ijms17010028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
24 Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. J Am Soc Nephrol. 2020;31:1628-1639. [PMID: 32493693 DOI: 10.1681/asn.2019060623] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 20.0] [Reference Citation Analysis]
25 Barraclough KA, Hawley CM, Playford EG, Johnson DW. Prevention of access-related infection in dialysis. Expert Review of Anti-infective Therapy 2014;7:1185-200. [DOI: 10.1586/eri.09.100] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
26 Besarab A. Anemia and iron management. Semin Dial 2011;24:498-503. [PMID: 21906169 DOI: 10.1111/j.1525-139X.2011.00983.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Luo J, Jensen DE, Maroni BJ, Brunelli SM. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients. Am J Kidney Dis 2016;68:763-71. [PMID: 27528373 DOI: 10.1053/j.ajkd.2016.05.031] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
28 Fernandes JC, Garrido P, Ribeiro S, Rocha-Pereira P, Bronze-da-Rocha E, Belo L, Costa E, Reis F, Santos-Silva A. Iron as the key modulator of hepcidin expression in erythroid antibody-mediated hypoplasia. Biomed Res Int 2014;2014:421304. [PMID: 25580431 DOI: 10.1155/2014/421304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Oshiro Y, Tanaka H, Okimoto N. A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet. Clin Exp Nephrol 2011;15:607-10. [DOI: 10.1007/s10157-011-0433-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Borawski B, Malyszko JS, Kwiatkowska M, Malyszko J. Current Status of Renal Anemia Pharmacotherapy-What Can We Offer Today. J Clin Med 2021;10:4149. [PMID: 34575261 DOI: 10.3390/jcm10184149] [Reference Citation Analysis]
31 Mc Causland FR, Claggett B, Pfeffer MA, Burdmann EA, Eckardt KU, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol 2017;46:488-97. [PMID: 29241199 DOI: 10.1159/000485326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
32 van der Meer P, Grote Beverborg N, Pfeffer MA, Olson K, Anand IS, Westenbrink BD, McMurray JJV, Swedberg K, Young JB, Solomon SD, van Veldhuisen DJ. Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations. Circ Heart Fail 2018;11:e004431. [PMID: 29367268 DOI: 10.1161/CIRCHEARTFAILURE.117.004431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Saifan C, Samarneh M, Shtaynberg N, Nasr R, El-Charabaty E, El-Sayegh S. Treatment of confirmed B12 deficiency in hemodialysis patients improves Epogen® requirements. Int J Nephrol Renovasc Dis 2013;6:89-93. [PMID: 23776388 DOI: 10.2147/IJNRD.S44660] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
34 Kun S, Mikolás E, Molnár GA, Sélley E, Laczy B, Csiky B, Kovács T, Wittmann I. Association of plasma ortho-tyrosine/para-tyrosine ratio with responsiveness of erythropoiesis-stimulating agent in dialyzed patients. Redox Rep 2014;19:190-8. [PMID: 24693974 DOI: 10.1179/1351000214Y.0000000090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
35 Killen JP, Brenninger VL. Hydroxocobalamin supplementation and erythropoisis stimulating agent hyporesponsiveness in haemodialysis patients. Nephrology (Carlton) 2014;19:164-71. [PMID: 24422907 DOI: 10.1111/nep.12205] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Durussel J, Haile DW, Mooses K, Daskalaki E, Beattie W, Mooses M, Mekonen W, Ongaro N, Anjila E, Patel RK, Padmanabhan N, Mcbride MW, Mcclure JD, Pitsiladis YP. Blood transcriptional signature of recombinant human erythropoietin administration and implications for antidoping strategies. Physiological Genomics 2016;48:202-9. [DOI: 10.1152/physiolgenomics.00108.2015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
37 Akizawa T, Yamaguchi Y, Otsuka T, Reusch M. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis. Nephron 2020;144:372-82. [PMID: 32580188 DOI: 10.1159/000508100] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
38 Groenendaal-van de Meent D, Kerbusch V, Kaspera R, Barroso-Fernandez B, Galletti P, Klein GK, den Adel M. Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. Eur J Drug Metab Pharmacokinet 2021;46:141-53. [PMID: 33165773 DOI: 10.1007/s13318-020-00658-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Merchant ML, Gaweda AE, Dailey AJ, Wilkey DW, Zhang X, Rovin BH, Klein JB, Brier ME. Oncostatin M receptor β and cysteine/histidine-rich 1 are biomarkers of the response to erythropoietin in hemodialysis patients. Kidney Int 2011;79:546-54. [PMID: 21150872 DOI: 10.1038/ki.2010.468] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
40 Hanna RM, Streja E, Kalantar-Zadeh K. Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. Adv Ther 2021;38:52-75. [PMID: 33123967 DOI: 10.1007/s12325-020-01524-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Wärme A, Hadimeri H, Nasic S, Stegmayr B. The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis. BMC Nephrol 2021;22:30. [PMID: 33461526 DOI: 10.1186/s12882-020-02209-6] [Reference Citation Analysis]
42 Patel SK, Griggs MR, Ghoneim YM, Malhotra CK, Fenves AZ, Jacob SC. Evaluation of the use of erythropoietin-stimulating agents in a hospital setting to assess the necessity of a protocol-driven anemia management service. Proc (Bayl Univ Med Cent) 2020;33:191-4. [PMID: 32313459 DOI: 10.1080/08998280.2020.1723360] [Reference Citation Analysis]
43 van Haelst IMM, Egberts ACG, Doodeman HJ, van Solinge WW, Kalkman CJ, Bennis M, Traast HS, van Klei WA. Occurrence and determinants of poor response to short-term pre-operative erythropoietin treatment: Poor response to pre-operative erythropoietin. Acta Anaesthesiol Scand 2013;57:350-7. [DOI: 10.1111/aas.12029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
44 Wijnberge M, Rellum SR, Bruin S, Cecconi M, Oczkowski S, Vlaar AP. Erythropoiesis‐stimulating agents as replacement therapy for blood transfusions in critically ill patients with anaemia: A systematic review with meta‐analysis. Transfusion Medicine 2020;30:433-41. [DOI: 10.1111/tme.12715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT, Leong R, Poole L, Zhong M, Saikali KG, Franco M, Hemmerich S, Yu KH, Neff TB. Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients. J Am Soc Nephrol. 2016;27:1225-1233. [PMID: 26494833 DOI: 10.1681/asn.2015030241] [Cited by in Crossref: 140] [Cited by in F6Publishing: 72] [Article Influence: 20.0] [Reference Citation Analysis]
46 Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y, Fukuhara S. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis. 2012;59:108-116. [PMID: 21890255 DOI: 10.1053/j.ajkd.2011.07.014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
47 Louw EH, Chothia MY. Residual renal function in chronic dialysis is not associated with reduced erythropoietin-stimulating agent dose requirements: a cross-sectional study. BMC Nephrol 2017;18:336. [PMID: 29178879 DOI: 10.1186/s12882-017-0752-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
48 Akizawa T, Yamaguchi Y, Majikawa Y, Reusch M. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Ther Apher Dial 2021;25:575-85. [PMID: 33200512 DOI: 10.1111/1744-9987.13609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Ashry OM, Hasan HF. The Evolving Role of Erythropoietin in Lung of Irradiated Rats. Braz arch biol technol 2017;60. [DOI: 10.1590/1678-4324-2017160800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Mandolfo S, Corradi B, Bucci R, Farina M, Pilolli F, Galli F. Evaluation of the impact of a new synthetic vitamin E-bonded membrane on anemia and rHuEPO requirement in ESRD patients with central venous catheters: a pilot study. Int Urol Nephrol. 2012;44:1493-1500. [PMID: 21960369 DOI: 10.1007/s11255-011-0016-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
51 Afsar B, Agca E, Turk S. Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol. J Clin Pharmacol 2015;55:1280-5. [PMID: 26032009 DOI: 10.1002/jcph.556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
52 Muchnik E, Kaplan J. HIF prolyl hydroxylase inhibitors for anemia. Expert Opin Investig Drugs 2011;20:645-56. [PMID: 21406036 DOI: 10.1517/13543784.2011.566861] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
53 Khankin EV, Mutter WP, Tamez H, Yuan HT, Karumanchi SA, Thadhani R. Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. PLoS One 2010;5:e9246. [PMID: 20169072 DOI: 10.1371/journal.pone.0009246] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
54 Ogawa T, Shimizu H, Kyono A, Sato M, Yamashita T, Otsuka K, Nitta K. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study. Int Urol Nephrol 2014;46:151-9. [PMID: 23807369 DOI: 10.1007/s11255-013-0494-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
55 Barrett TD, Palomino HL, Brondstetter TI, Kanelakis KC, Wu X, Yan W, Merton KP, Schoetens F, Ma JY, Skaptason J, Gao J, Tran DT, Venkatesan H, Rosen MD, Shankley NP, Rabinowitz MH. Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol 2015;172:4078-88. [PMID: 25988595 DOI: 10.1111/bph.13188] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
56 Yeun JY, Ornt DB, Depner TA. Hemodialysis. Brenner and Rector's The Kidney. Elsevier; 2012. pp. 2294-346. [DOI: 10.1016/b978-1-4160-6193-9.10064-8] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
57 Hou YP, Mao XY, Wang C, Xu ZH, Bu ZH, Xu M, Li B. Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial. J Formos Med Assoc 2021:S0929-6646(21)00250-3. [PMID: 34167878 DOI: 10.1016/j.jfma.2021.06.004] [Reference Citation Analysis]
58 Gomez-Alamillo C, Fernández-Fresnedo G, Ortega F, Campistol JM, Gentil MA, Arias M; Investigators of ARES Study. Erythropoietin resistance as surrogate marker of graft and patient survival in renal transplantation: 3-year prospective multicenter study. Transplant Proc 2010;42:2935-7. [PMID: 20970575 DOI: 10.1016/j.transproceed.2010.07.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
59 Kuwahara M, Arai Y, Takehara E, Sasaki Y, Yoshimine T, Kusaka K, Shikuma S, Akita W, Uchida S. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients. Clin Exp Nephrol 2016;20:585-94. [PMID: 26511877 DOI: 10.1007/s10157-015-1188-x] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
60 Flythe JE, Li NC, Lin SF, Brunelli SM, Hymes J, Lacson E Jr. Associates of cardiopulmonary arrest in the perihemodialytic period. Int J Nephrol 2014;2014:961978. [PMID: 25530881 DOI: 10.1155/2014/961978] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
61 Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121 [PMID: 34909408 DOI: 10.5527/wjn.v10.i6.109] [Reference Citation Analysis]
62 Macdougall IC. Development of Recombinant Erythropoietin and Erythropoietin Analogs. Textbook of Nephro-Endocrinology. Elsevier; 2018. pp. 217-32. [DOI: 10.1016/b978-0-12-803247-3.00013-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Myllymäki MNM, Määttä J, Dimova EY, Izzi V, Väisänen T, Myllyharju J, Koivunen P, Serpi R. Notch Downregulation and Extramedullary Erythrocytosis in Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 2-Deficient Mice. Mol Cell Biol 2017;37:e00529-16. [PMID: 27821476 DOI: 10.1128/MCB.00529-16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
64 Pineault J, Lamarche C, Bell R, Lafrance JP, Ouellet G, Leblanc M, Pichette V, Bezzaoucha S, Vallée M. Association of Neutrophil-to-Lymphocyte Ratio With Inflammation and Erythropoietin Resistance in Chronic Dialysis Patients. Can J Kidney Health Dis 2017;4:2054358117735563. [PMID: 29147572 DOI: 10.1177/2054358117735563] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
65 Naini AE, Hedaiati ZP, Gholami D, Pezeshki AH, Moinzadeh F. The effect of Vitamin D administration on treatment of anemia in end-stage renal disease patients with Vitamin D deficiency on hemodialysis: A placebo-controlled, double-blind clinical trial. J Res Med Sci 2015;20:745-50. [PMID: 26664421 DOI: 10.4103/1735-1995.168375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
66 Garvican-Lewis LA, Vuong VL, Govus AD, Schumacher YO, Hughes D, Lovell G, Eichner D, Gore CJ. Influence of combined iron supplementation and simulated hypoxia on the haematological module of the athlete biological passport. Drug Test Anal 2018;10:731-41. [PMID: 28929623 DOI: 10.1002/dta.2303] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
67 Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger O, Ozgurtas T, Yenicesu M, Lindholm B, Stenvinkel P. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant. 2012;27:709-715. [PMID: 21617198 DOI: 10.1093/ndt/gfr288] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
68 Kao CC, Wong HS, Wang YJ, Chou WH, Perwitasari DA, Wu MS, Chang WC. The role of genetic polymorphisms in STIM1 and ORAI1 for erythropoietin resistance in patients with renal failure. Medicine (Baltimore) 2021;100:e25243. [PMID: 33907089 DOI: 10.1097/MD.0000000000025243] [Reference Citation Analysis]
69 Rottembourg JB, Dansaert A. Faisabilité de la stratégie d’administration de la darbepoetin alfa tous les 15 jours : expérience 2005–2007 d’un centre de dialyse. Néphrologie & Thérapeutique 2011;7:549-57. [DOI: 10.1016/j.nephro.2011.03.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
70 Ngo K, Kotecha D, Walters JA, Manzano L, Palazzuoli A, van Veldhuisen DJ, Flather M. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010;:CD007613. [PMID: 20091643 DOI: 10.1002/14651858.CD007613.pub2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
71 van der Weerd NC, Den Hoedt CH, Blankestijn PJ, Bots ML, van den Dorpel MA, Lévesque R, Mazairac AH, Nubé MJ, Penne EL, ter Wee PM, Grooteman MP; CONTRAST Investigators. Resistance to erythropoiesis stimulating agents in patients treated with online hemodiafiltration and ultrapure low-flux hemodialysis: results from a randomized controlled trial (CONTRAST). PLoS One 2014;9:e94434. [PMID: 24743493 DOI: 10.1371/journal.pone.0094434] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
72 Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One 2014;9:e111838. [PMID: 25392999 DOI: 10.1371/journal.pone.0111838] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 10.8] [Reference Citation Analysis]
73 Soni H. Prolyl hydroxylase domain-2 (PHD2) inhibition may be a better therapeutic strategy in renal anemia. Medical Hypotheses 2014;82:547-50. [DOI: 10.1016/j.mehy.2014.02.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
74 Ribeiro S, Garrido P, Fernandes J, Vala H, Rocha-Pereira P, Costa E, Belo L, Reis F, Santos-Silva A. Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia. Biochimie 2016;125:150-62. [PMID: 27039028 DOI: 10.1016/j.biochi.2016.03.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
75 Matsumura K, Okumiya T, Sugiura T, Takahashi N, Yamamoto Y, Kikuchi S, Fujii K, Otagaki M, Shiojima I. Shortened red blood cell age in patients with end-stage renal disease who were receiving haemodialysis: a cross-sectional study. BMC Nephrol 2020;21:418. [PMID: 32993543 DOI: 10.1186/s12882-020-02078-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Gilbertson DT, Peng Y, Arneson TJ, Dunning S, Collins AJ. Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics. BMC Nephrol 2013;14:44. [PMID: 23425362 DOI: 10.1186/1471-2369-14-44] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
77 Macdougall IC. Epoetin-induced pure red cell aplasia: diagnosis and treatment. Curr Opin Nephrol Hypertens 2007;16:585-8. [PMID: 18089975 DOI: 10.1097/MNH.0b013e3282f0c4bf] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
78 Ganz T, Nemeth E. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. Semin Nephrol 2016;36:87-93. [PMID: 27236128 DOI: 10.1016/j.semnephrol.2016.02.001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 18.3] [Reference Citation Analysis]